Halozyme Therapeutics, Inc. (LON:0J2O)
76.32
-0.71 (-0.92%)
At close: Sep 15, 2025
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $325.72M USD in the quarter ending June 30, 2025, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.18B, up 34.97% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+34.97%
P/S Ratio
7.54
Revenue / Employee
$3.37M
Employees
350
Market Cap
6.49B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Halozyme Therapeutics News
- 9 days ago - Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript - Seeking Alpha
- 15 days ago - Insider Sell: Bernadette Connaughton Sells 4,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
- 19 days ago - Identify Superstar Stocks Like Halozyme with Money Flows - FX Empire
- 20 days ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - What Does the Market Think About Halozyme Therapeutics? - Benzinga
- 6 weeks ago - Halozyme up after guidance raise, Morgan Stanley upgrade - Seeking Alpha
- 6 weeks ago - Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts - Seeking Alpha